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Abstract  Tuberculosis  is  the  most  prevalent  infection  worldwide.  The  emergence
of  drug-resistant  Mycobacterium  tuberculosis  (M.  tuberculosis)  isolates  emphasizes
that  it  is  necessary  to  monitor  drug  resistance  of  the  organism  against  anti-tubercular
drugs.  We  analyzed  327  M.  tuberculosis  isolates  from  patients  who  were  cared  for
at  three  different  health  care  centers,  hereinafter  known  as  study  areas  (SAs),  in
North  India.  Of  the  327  total  M.  tuberculosis  isolates,  255  were  from  a  tertiary  health
care  center  (Varanasi,  Uttar  Pradesh  [SA-1]),  48  were  from  a  District  tuberculosis
center  (Sawai  Madhopur,  Rajasthan  [SA-2]),  and  24  were  from  a  different  District
tuberculosis  center  (Buxar,  Bihar  [SA-3]).  Drug  susceptibility  testing  against  ﬁrst-line
antibiotics  (viz.  isoniazid,  rifampicin,  streptomycin,  and  ethambutol)  was  conducted
for  all  the  isolates  using  1%  proportional  method.  We  found  that  the  rates  of  acquired
resistance  were  consistently  higher  than  the  rates  of  initial  drug  resistance.  In  new,
untreated  cases,  a  higher  degree  of  MDR-TB  was  observed  at  SA-1  (13.3%)  and  SA-3
(25.0%),  whereas  it  was  observed  in  only  7.1%  of  the  isolates  at  SA-2.  In  previously
treated  patients,  MDR  cases  were  found  in  35.7%  of  the  isolates  from  SA-1,  66.6%  of
the  isolates  from  SA-2,  and  43.8%  of  the  isolates  from  SA-3.  Resistance  to  a  single
drug  was  found  at  a  much  lower  rate,  ranging  from  0.0  to  6.3%  in  new  cases  as  well
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Drug  susceptibility  patterns  of  M.  tuberculosis  
as  previously  treated  cases.  
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uberculosis  (TB)  in  humans  has  been  described
ince ancient  times.  Its  causative  agent,  Mycobac-
erium  tuberculosis  (MTB),  is  widely  disseminated.
espite mass  Mycobacterium  bovis  BCG  vaccina-
ion and  the  development  of  antitubercular  drugs,
uberculosis  still  remains  a  major  global  public
ealth problem.  The  WHO  estimates  that  approx-
mately one-third  of  the  global  community  is
nfected  with  M.  tuberculosis  [1]. World-wide,
here were  an  estimated  8.8  million  TB  cases  in
010.  Additionally,  during  that  same  year,  1.1  mil-
ion deaths  in  HIV-negative  individuals  and  0.35
illion deaths  in  HIV-positive  individuals  were  due
o TB.  These  statistics  make  TB  the  world’s  lead-
ng cause  of  mortality  [2].  According  to  the  RNTCP
tatus  report-2012,  India  had  2 million  reported  TB
ases, which  was  responsible  for  one-ﬁfth  of  the
lobal burden  [3].
Isoniazid  (INH),  ethambutol,  rifampicin,  pyraz-
namide,  and  streptomycin  are  important  com-
onents of  ﬁrst-line  anti-tubercular  regimens.  A
ombination  of  isoniazid  (INH)  and  rifampicin  (RIF)
orm the  cornerstone  of  short  course  chemotherapy
or TB.  As  a  result,  resistance  to  either  drug  seri-
usly  hampers  the  achievement  of  a  complete  cure
f the  patient.  The  emergence  of  drug-resistant
trains of  MTB  is  an  increasing  problem  in  both
he developed  world  and  developing  countries.
rug resistance  can  be  primary  or  acquired.  Pri-
ary drug  resistance  is  deﬁned  as  drug  resistance
n a  patient  who  has  not  received  any  past  anti-
ubercular treatment.  The  resistance  that  develops
n a  patient  who  has  received  prior  chemotherapy
s deﬁned  as  acquired  drug  resistance.  Strains  of
. tuberculosis  that  are  resistant  to  both  isoni-
zid and  rifampicin,  with  or  without  resistance  to
ther drugs,  have  been  termed  multidrug  resistant
trains  (MDRs).  This  is  an  emerging  problem  and
as great  importance  to  public  health  worldwide.
everal reports  have  indicated  that  drug  resistance
s increasing  among  pulmonary  TB  patients  in  India
4—6].  However,  various  Indian  studies  have  shown
hat the  rate  of  MDR-TB  is  very  low  (0—6%)  [7].
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In  conclusion,  the  primary  resistance  of  M.  tuberculosis
istance  is  slightly  higher  in  North  India.
ziz  University  for  Health  Sciences.  Published  by  Elsevier
Levels  and  trends  of  drug  resistance  vary  by
ocation [8]. Additionally,  drug  resistance  serves  as
n epidemiological  indicator,  which  allows  investi-
ators to  assess  the  extent  of  resistant  bacterial
ransmission in  the  community  [6]. Therefore,  drug
esistance  surveillance  (DRS)  is  considered  a  useful
ool to  assess  the  drug  susceptibility  proﬁle  among
ewly  diagnosed  and  previously  treated  patients,
s well  as  to  determine  the  effective  functioning
f TB  control  programs  [8]. Early  identiﬁcation  of
rug-resistant  strains,  particularly  MDR  strains,  is
rucial in  order  to  permit  the  timely  administration
f appropriate  drug  regimens  and  minimize  trans-
ission  of  these  strains.
Considering  the  above  facts,  the  purpose  of  the
resent  study  was  to  assess  the  drug  susceptibil-
ty proﬁle  of  M.  tuberculosis  strains  isolated  from
atients  receiving  care  at three  different  hospital
enters  in  North  India.
aterials and methods
pecimen collection
pecimens  were  obtained  from  three  different  loca-
ions in  North  India  between  October  2004  and
ecember 2007.  The  study  populations  were  as
ollows:  (1)  patients  from  eastern  Uttar  Pradesh
ho received  care  from  the  Outpatient  Depart-
ent (OPD)  of TB  &  Respiratory  Diseases  and  Urban
ealth Centre,  Sunderpur,  in  the  Department  of
ommunity  medicine  at  the  Institute  of  Medical  Sci-
nces, Banaras  Hindu  University,  Varanasi  (SA-1);
2) patients  from  the  district  tuberculosis  center,
awai Madhopur,  Rajasthan  (SA-2);  and  (3)  patients
rom the  district  tuberculosis  center,  Buxar,  Bihar
SA-3). The  957  samples  from  SA-1  consisted  of  spu-
um (655),  endometrial  tissues  (69),  pus  (67),  urine
37), pleural  ﬂuid  (35),  gastric  aspirate  (33),  cere-
rospinal  ﬂuid  (29),  bronchoalveolar  lavage  (13),
nee aspirate  (7),  ascitic  ﬂuid  (6),  and  lymph  node
spirate  (6).  A  total  of  81  sputum  samples  were
eceived  from  SA-2,  while  42  sputum  samples  were
ollected  from  SA-3.
S
O
S
v
o
t
s
2
c
S
T
v
c
p
w
f
t
D
T
m
s
m
n
a
s
n
h
e
r
m
M
o
f
i
a
w
h
w
l
r
m
s
w
t
[458  
Isolation and characterization
All  1080  specimens  were  processed  by  modiﬁed
Petroffs method  in  the  Department  of  Microbiol-
ogy, Institute  of  Medical  Sciences,  Banaras  Hindu
University,  Varanasi.  The  identiﬁcation  and  char-
acterization  of  isolates  were  conducted  using
standard methods,  such  as  colony  characterization,
a niacin  test,  a  heat-sensitive  catalase  test,  and  a
test to  assess  growth  on  PNB-containing  LJ  media
[9].
Drug susceptibility test
All  M.  tuberculosis  isolates  were  subjected  to
drug susceptibility  testing  by  using  the  1%  propor-
tion method  on  LJ-medium.  M.  tuberculosis  strain
H37Rv  was  used  as  sensitive  control  for  the  suscep-
tibility testing  [10].
Statistical analysis
Data  were  entered,  and  the  95%  conﬁdence  interval
was analyzed  using  SPSS  statistical  software.
Results
Strain collection
Of  the  1080  specimens,  we  isolated  388  mycobac-
terial isolates.  After  biochemical  characterization,
327 (84.3%)  were  identiﬁed  as  M.  tuberculosis
and 61  (15.7%)  were  identiﬁed  as  non-tubercular
mycobacteria  (NTM).  Among  the  327  M.  tubercu-
losis isolates,  255,  48,  and  24  were  isolated  from
SA-1, SA-2,  and  SA-3,  respectively.
Drug susceptibility testing
SA-1
Drug  susceptibility  testing  of  the  255  M.  tuber-
culosis isolates  (from  98  new  and  157  previously
treated patients)  was  performed  using  1%  propor-
tion method.  Among  the  new  cases,  13  (13.3%)
were MDR.  In  the  isolates  from  previously  treated
patients, 56  (35.7%)  were  MDR.  The  number  of  iso-
lates that  were  sensitive  to  all  drugs  was  higher  in
new cases  (n  =  69,  70.4%)  compared  with  previously
treated cases  (n  =  77,  49.0%).  Resistance  to  isoni-
azid was  found  to  be  highest  in  new  (n  =  23,  23.5%),
as well  as  in  previously  treated  (n  =  78,  49.7%)  cases
(Table  1).
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A-2
f  the  48  M.  tuberculosis  isolates  collected  from
A-2,  42  were  from  new  cases  and  6  were  from  pre-
iously  treated  cases.  We  found  a higher  percentage
f MDR  (66.9%)  cases  in  isolates  from  previously
reated cases  than  in  new  cases  (7.1%),  whereas
ensitivity to  all  drugs  was  found  in  35  (83.3%)  and
 (33.3%)  isolates  from  new  and  previously  treated
ases,  respectively  (Table  2).
A-3
wenty-four isolates  (8  from  new  and  16  from  pre-
iously  treated  cases)  were  subjected  to  DST.  MDR
ases were  found  in  25.0%  of  new  and  43.8%  of
reviously  treated  cases.  Sensitivity  to all  drugs
as assessed  in  5  (62.5%)  and  6  (37.5%)  isolates
rom new  and  previously  treated  cases,  respec-
ively (Table  3).
iscussion
he  present  study  has  generated  valuable  infor-
ation regarding  the  drug-resistant  tuberculosis
ituation in  new  and  treated  cases  in  India.  The
ajor reasons  for  the  occurrence  of  MDR  are  the
on-adherence  of  patients  to  prescribed  treatment
nd/or  inappropriate  drug  regimens.  Additionally,
ocio-economic factors  that  may  contribute  to
on-adherence  of  treatment  are  drug  abuse,  alco-
olism,  poverty,  and  homelessness  [11]. A  lack  of
valuation of  program  indicators,  especially  cure
ates, is also  important.  Previous  inadequate  treat-
ent has  been  the  most  consistent  predictor  of
DR-TB [12].
Among  new  cases,  resistance  to  any  drug  was
bserved in  30.6,  16.7,  and  37.5%  of the  isolates
rom SA-1,  SA-2,  and  SA-3,  respectively.  Our  ﬁnd-
ngs indicate  that  there  is  a higher  percentage  of
ny drug  resistance  in  SA-1  and  SA-3  compared
ith that  in  the  Thiruvallur,  Hoogli,  and  Mayurb-
anj districts,  where  resistance  to  any  tested  drug
as only  found  in  15,  16.7,  and  5.3%  of the  iso-
ates, respectively  [13,14].  However,  in  SA-2,  the
esistance was  similar  to  that  in  the  previously
entioned studies.  The  resistance  rates  from  our
tudy are  slightly  higher  than  the  global  summary,
hich reported  a  median  primary  resistance  of  9.9%
o any  of  the  anti-TB  drugs  and  an  MDR  of  1.4%
16].
In SA-1,  SA-2,  and  SA-3,  69.4,  83.3,  and  62.5%
f the  isolates,  respectively,  were  sensitive  to  all
our tested  ﬁrst-line  drugs  (INH,  RIF,  SM,  and  EMB).
imilar results  were  reported  in  a  study  from  North
rcot and  Pondicherry,  which  showed  that  75  and
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Table  1  Drug  resistance  proﬁle  of  M.  tuberculosis  isolates  from  patients  of  SA-1.
S.  No.  New  (n  =  98)  Previously  treated  (n  =  157)
n %  95%  CI  n  %  95%  CI
1  Sensitive  to  all  drugs  69  70.4  60.7—78.5  77  49.0  41.3—56.8
2  Resistant  to  all  drugs 6  6.1 2.8—12.7 39  24.8  18.7—32.1
3  MDR  13  13.3 7.9—21.4 56  35.7  28.6—43.4
4  Any  drug  resistance  29  29.6  21.5—39.3  80  51.0  43.2—58.7
5  Resistant  to  Isoniazid  23  23.5  16.2—32.8  78  49.7  42—57.4
6  Resistant  to  Ethambutol  12  12.2  7.2—20.2  55  35.0  28.0—42.8
7  Resistant  to  Streptomycin  13  13.3  7.9—21.4  59  37.6  30.4—45.4
8  Resistant  to  Rifampicin  16  16.3  10.3—24.9  62  39.5  32.2—47.3
9  Resistant  to  Isoniazid  alone  3  3.1  1.1—8.6  2  1.3  0.4—4.5
10  Resistant  to  Ethambutol  alone  1  1.0  0.2—5.6  3  1.9  0.7—5.4
11  Resistant  to  Streptomycin  alone  2  2.0  0.6—7.1  1  0.6  0.1—3.5
12  Resistant  to  Rifampicin  alone  0  0.0  0  0.0
13  Resistant  to  HES  6  6.1  2.8—12.7  41  26.1  19.9—33.5
14  Resistant  to  HER  7  7.1  3.5—14.0  40  25.5  19.3—32.8
15  Resistant  to  ESR  6  6.1  2.8—12.7  39  24.8  18.7—32.1
16  Resistant  to  HSR  8  8.2  4.2—15.3  43  27.4  21.0—34.8
17  Resistant  to  HE  10  10.2  5.6—17.8  45  28.7  22.2—36.2
18  Resistant  to  HS  9  9.2  4.9—16.5  53  33.8  26.8—41.5
19  Resistant  to  ES  6  6.1  2.8—12.7  47  29.9  23.3—37.5
20  Resistant  to  ER  8  8.2  4.2—15.3  44  28.0  21.6—35.5
21  Resistant  to  SR  10  10.2  5.6—17.8  45  28.7  22.2—36.2
H: Isoniazid; R: Rifampicin; E: Ethambutol; S: Streptomycin; MDR: multi drug resistant.
Table  2  Drug  resistance  proﬁle  of  M.  tuberculosis  isolates  from  patients  of  SA-2.
S.  No.  New  (n  =  42)  Previously  treated  (n  =  6)
n  %  95%  CI  n  %  95%  CI
1  Sensitive  to  all  drugs 35  83.3  69.4—91.7  2  33.3  9.7—70
2  Resistant  to  all  drugs 2  4.8  1.3—15.8  3  50.0  18.8—81.2
3  MDR  3  7.1  2.5—19.0  4  66.6  30.0—90.3
4  Any  drug  resistance  7  16.7  8.3—30.6  4  66.6  30.0—90.3
5  Resistant  to  Isoniazid  6  14.3  6.7—27.8  4  66.6  30.0—90.3
6  Resistant  to  Ethambutol  4  9.5  3.8—22.1  4  66.6  30.0—90.3
7  Resistant  to  Streptomycin  4  9.5  3.8—22.1  3  50.0  18.8—81.2
8  Resistant  to  Rifampicin  3  7.1  2.5—19.0  4  66.6  30.0—90.3
9  Resistant  to  Isoniazid  alone  2  4.8  1.3—15.8  0  0.0
10  Resistant  to  Ethambutol  alone  1  2.4  0.4—12.3  0  0.0
11  Resistant  to  Streptomycin  alone  0  0.0  0  0.0
12  Resistant  to  Rifampicin  alone  0  0.0  0  0.0
13  Resistant  to  HES  3  7.1  2.5—19.0  3  50.0  18.8—81.2
14  Resistant  to  HER  2  4.8  1.3—15.8  4  66.6  30.0—90.3
15  Resistant  to  ESR  2  4.8  1.3—15.8  3  50.0  18.8—81.2
16  Resistant  to  HSR  3  7.1  2.5—19.0  3  50.0  18.8—81.2
17  Resistant  to  HE  3  7.1  2.5—19.0  4  66.6  30.0—90.3
18  Resistant  to  HS  4  9.5  3.8—22.1  3  50.0  18.8—81.2
19  Resistant  to  ES  3  7.1  2.5—19.0  3  50.0  18.8—81.2
20  Resistant  to  ER  2  4.8  1.3—15.8  4  66.6  30.0—90.3
21  Resistant  to  SR  3  7.1  2.5—19.0  3  50.0  18.8—81.2
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Table  3  Drug  resistance  proﬁle  of  M.  tuberculosis  isolates  collected  from  SA-3.
S.  No.  New  (n  =  8)  Previously  treated  (n  =  16)
n  %  95%  CI  n  %  95%  CI
1  Sensitive  to  all  drugs  5  62.5  30.6—86.3  6  37.5  18.5—61.4
2  Resistant  to  all  drugs 1  12.5 2.2—47.1 4  25.0  10.2—49.5
3  MDR  2  25.0 7.2—59.1 7  43.8  23.1—66.8
4  Any  drug  resistance  3  37.5  13.7—69.4  10  62.5  38.6—51.5
5  Resistant  to  Isoniazid  3  37.5  13.7—69.4  7  43.8  23.1—66.8
6  Resistant  to  Ethambutol  2  25.0  7.2—59.1  8  50.0  28.0—72.0
7  Resistant  to  Streptomycin  1  12.5  2.2—47.1  6  37.5  18.5—61.4
8  Resistant  to  Rifampicin  2  25.0  7.2—59.1  7  43.8  23.1—66.8
9  Resistant  to  Isoniazid  alone  0  0.0  0  0.0
10  Resistant  to  Ethambutol  alone  0  0.0  1  6.3  1.1—28.3
11  Resistant  to  Streptomycin  alone  0  0.0  0  0.0
12  Resistant  to  Rifampicin  alone  0  0.0  0  0.0
13  Resistant  to  HES  1  12.5  2.2—47.1  4  25.0  10.2—49.5
14  Resistant  to  HER  1  12.5  2.2—47.1  5  31.3  14.2—55.6
15  Resistant  to  ESR  1  12.5  2.2—47.1  4  25.0  10.2—49.5
16  Resistant  to  HSR  1  12.5  2.2—47.1  4  25.0  10.2—49.5
17  Resistant  to  HE  2  25.0  7.2—59.1  5  31.3  14.2—55.6
18  Resistant  to  HS  1  12.5  2.2—47.1  4  25.0  10.2—49.5
19  Resistant  to  ES  1  12.5  2.2—47.1  6  37.5  18.5—61.4
20  Resistant  to  ER  1  12.5  2.2—47.1  5  31.3  14.2—55.6
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87%  of  the  new  cases  respectively  had  organisms
susceptible to  SM,  INH,  and  RIF  [17].  The  National
Tuberculosis Institute  also  reported  a  similar  pat-
tern; namely,  65  and  79%  of  patients  in  Bangalore
city and  in  a  rural  area  of  Karnataka,  respectively,
had organisms  susceptible  to  SM,  INH,  and  RIF  [18].
The ﬁrst  global  surveillance  study,  performed
between 1994  and  1997  [8],  reported  that  90%
of newly  diagnosed  pulmonary  TB  (PTB)  patients
were infected  by  organisms  that  were  suscepti-
ble to  SM,  INH,  and  RIF.  MDR-TB  was  found  among
1.4% of  patients  (range  0—14%)  from  35  countries
across 5  continents.  The  second  surveillance  dur-
ing 1996—1999  reported  consistent  results.  In  this
study,  89%  of  patients  were  infected  by  orga-
nisms that  were  susceptible  to  SM,  INH,  and  RIF
(range  63—98%),  while  1%  of  patients  were  found
to have  MDR-TB  (range  0—14.2%).  The  patients  in
this study  were  from  72  geographical  settings  [19].
The corresponding  values  for  the  third  surveillance
during 1999—2002  were  90%  (43—100%)  and  1.1%
(0—14.2%), respectively,  from  75  geographical  sett-
ings [20].
The fourth  report  of  the  WHO/IUATLD  Global
Project on  Anti-Tuberculosis  Drug  Resistance
Surveillance  (2002—2007)  reported  that  the
proportion of  resistance  to  at  least  one  anti-
tubercular drug  (any  resistance)  ranged  from  0%  in
two Western  European  countries  to  56.3%  in  Baku,
Azerbaijan.  The  proportion  of  MDR  ranged  from  0%
s
I
T
t.5  2.2—47.1  4  25.0  10.2—49.5
n  8 countries  to  22.3%  in  Baku,  Azerbaijan,  and
9.4% in  the  Republic  of  Moldova  [21].
The INH  form  of resistance  is  the  most  com-
on resistance  reported  globally  from  TB  isolates,
ollowed  by  rifampicin  and  streptomycin  [22]. In
he current  study,  the  initial  INH  resistance  in  SA-
 (23.5%)  was  found  to  be  similar  to  that  in  studies
rom North  Arcot  (23.4%),  Raichur  (18.7%),  and  Ban-
alore (17.4%).  However,  the  resistance  percentage
rom  our  study  was  higher  than  that  in  studies  from
amil Nadu  (15%),  Jaipur  (10%),  Madras  (10.6%),
oogli  (10.3%),  Mayurbhanj  (2.5%),  and  the  Thiru-
allur district  (10.4%)  of  India  (23,  6, 24,  13,  14).
he INH  resistance  of  isolates  from  SA-2  (14.3%)
as found  to  be  similar  to  that  in  the  previously
eferenced  studies  from  Raichur,  Bangalore,  and
amilnadu.  However,  in  SA-3,  the  INH  resistance
37.5%) was  found  to  be  higher  than  that  in  all  the
bove-mentioned  studies  but  similar  to  that  in  a
tudy from  Kolar  (32.8%)  [24].  A  higher  INH  resis-
ance (54.2%)  was  reported  from  Indore  [5].
The level  of  resistance  to  INH  is  alarming  in  all
he three  study  areas  (SA-1,  23.5%;  SA-2,  14.3%;  SA-
, 37.5%),  considering  that  INH  is  used  as  a ﬁrst-line
rug against  TB.  A  study  from  Chad  showed  that  INH
esistance was  found  in  27%  of  patients,  which  is
imilar to  our  ﬁndings  [15]. Primary  resistance  to
NH in  other  countries  has  been  reported  at  5.0%  in
anzania [25],  8%  in  Ethiopia  [26], 12.5%  in  Equa-
orial Guinea  [27],  and  12%  in  the  West  Province
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prug  susceptibility  patterns  of  M.  tuberculosis  
f  Cameroon  [28].  In  another  study  from  Uganda
nd Rwanda,  the  results  showed  that  8.1  and  6.2%
f isolates  were  resistant  to  isoniazid  [29].  A  higher
esistance  to  INH  (54.5%)  has  been  reported  in  China
30].
Resistance  to  rifampicin  was  found  in  16.2,  7.1,
nd 25.0%  of  the  isolates  from  SA-1,  SA-2,  and  SA-3,
espectively.  Compared  with  our  study,  rifampicin
esistance has  been  reported  to  be  lower  in  other
ndian  studies,  i.e.  2.5%  in  Hoogli,  0.7%  in  the
ayurbhanj district,  2.8%  in  the  North-Arcot  dis-
rict of Tamil  Nadu,  2.6%  in  Bangalore,  2.5%  in  the
aichur  district  of  Karnataka,  4.4%  in  Tamil  Nadu
nd 25%  in  Indore  [5,6,14,23,31].  At  the  global
evel, rifampicin  resistance  has  been  reported  at
.4% in  Uganda,  3.9%  in  Rwanda  [29],  0.7%  in  Tan-
ania [25],  and  58.7%  in  China  [30].
In the  present  study,  a  high  level  of  MDR-TB
as observed  in  isolates  from  SA-1  and  SA-3  (13.3
nd 25.0%,  respectively),  while  it  was  observed
n only  7.1%  isolates  from  SA-2.  With  regard  to
DR-TB  isolate  percentages,  other  Indian  studies
ave reported  0.4%  in  Hyderabad,  2.2%  in  Banga-
ore, 3.4%  in  Tamil  Nadu,  0.7%  in  Mayurbhanj,  3%  in
oogli, 1.7%  in  Thiruvallur,  2%  in  Jabalpur,  0.5%  in
ardha, 2.8%  in  North-Arcot,  and  2.5%  in  Raichur
6,13,14,23,31,32]. An  earlier  study  from  North
rcot and  Pondicherry  showed  that  among  new
ases, 1.7  and  0.8%  had  MDR-TB,  respectively  [17].
lobally, MDR  cases  have  been  reported  in  4.4,  3.9,
.4, and  46.3%  of  isolates  from  Uganda,  Rwanda,
anzania, and  China,  respectively  [25,29,30].
The resistance  to  ethambutol  in  new  cases  was
2.2, 9.5,  and  25.0%  in  isolates  from  SA-1,  SA-2,  and
A-3, respectively.  In  the  SA-3MTB  isolates,  etham-
utol resistance  was  found  to  be  higher  than  other
rug  resistance.  Ethambutol  resistance  in  SA-1  and
A-2 isolates  was  similar  to  that  in  a  study  in  Chad,
here 12%  of  isolates  were  ethambutol-resistant
15].  A  Tanzanian  study  did  not  ﬁnd  any  ethambutol-
esistant isolates  [25].  A  study  from  Indore  yielded
esults  indicating  that  there  was  a  high  resistance
o ethambutol  (22%),  which  is similar  to  our  ﬁndings
rom  SA-3  [5].
Streptomycin  resistance  was  not  as  high  as
esistance to  other  drugs.  Only  13.3%  of isolates
rom SA-1,  9.5%  of  isolates  from  SA-2,  and  12.5%
f isolates  from  SA-3  were  resistant  to  strepto-
ycin. A  study  from  Bangalore  and  Indore  found
treptomycin resistance  to  be  22.5%  and  41.5%,
espectively [5].  At  the  global  level,  a  Tanzanian
tudy reported  a  lower  primary  resistance  to  strep-
omycin  (0.7%)  [25].
In our  study,  the  rates  of  acquired  resistance
ere invariably  higher  than  those  of  primary  drug
esistance.  In  previously  treated  cases,  resistance
o
r
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o  any  drugs  was  similar  across  the  three  study
reas, with  percentages  of  any  drug  resistance
f 51.0%  of  isolates  from  SA-1,  66.6%  of  isolates
rom SA-2,  and  62.5%  of  isolates  from  SA-3.  Data
n acquired  resistance  are  limited  in  India.  A
tudy from  the  Thiruvallur  district  reported  any
rug resistance  in  41%  isolates  [13]. Similarly,  a
tudy from  Gujarat  reported  that  58.64%  of  iso-
ates showed  resistance  to  one  or  more  drugs,  while
5.21% of  isolates  were  resistant  to  all  four  drugs
33]. Resistance  to  all  drugs  was  found  in  24.8%  of
solates from  SA-1,  25.0%  of  isolates  from  SA-3,  and
0.0% of  isolates  from  SA-2.
In previously  treated  patients,  the  global  drug
esistance surveillance  reports  showed  that  59%
f patients  were  infected  by  organisms  that  were
usceptible  to  SM,  INH,  and  RIF,  while  12%  had
DR-TB [13].  In  a study  that  assessed  570  treat-
ent failure  and  relapse  pulmonary  tuberculosis
atients from  Amargadh,  Gujarat,  between  1980
nd 1986,  the  resistance  to  isoniazid  was  found
o be  44.24%,  resistance  to  rifampicin  was  found
n 22.9%  of  patients,  and  25.47%  of  patients  were
nfected  by  organisms  that  were  resistant  to  strep-
omycin  [34]. A  retrospective  study  from  New  Delhi
eported  MDR-TB  in  14%  of  isolates.  However,  57.5%
f the  isolates  were  sensitive  to  all  four  ﬁrst-line
rugs [35].  In  a study  conducted  in  Bangalore  city,
ijay et  al.  (2002)  reported  that  resistance  to  INH,
ither alone  or in  combination  with  another  drug,
as quite  high,  at  27.4%,  and  reported  SM  resis-
ance  at  23%  [36].
A study  from  New  Delhi  in  the  1990s  reported
 high  level  of  acquired  resistance  to  isoniazid
60.5%) and  rifampicin  (33.3%).  The  authors  also
eported a high  frequency  of  MDR  cases  (33.3%)
37].
A study  conducted  by  the  Institute  of  Thoracic
edicine in  Chennai  at  four  District  Tuberculosis
enters (DTCs)  of  Tamil  Nadu  showed  that  the  per-
entage  of  isolates  with  acquired  resistance  was
3%. Of  these,  23.5%  were  resistant  to  any  single
rug and  39.5%  were  resistant  to  more  than  one
rug. MDR-TB  was  reported  in  20.3%  of  the  isolates
38]. DRS  data  obtained  from  440  patients  from  the
odel DOTS  area  in  the  Thiruvallur  district  of  Tamil
adu (1999—2003)  revealed  that  the  incidence  of
DR TB  was  11.8%  [39].
A study  from  Patna,  Bihar,  reported  that  18%
f isolates  were  sensitive  to  all  the  drugs  tested.
dditionally, resistance  to  INH,  rifampicin  and  the
resence of  MDR  TB  were  found  in  80,  76,  and  72%
f cases,  respectively  [40].
Among previously  treated  patients,  the  ﬁrst  drug
esistance  surveillance  study  reported  that  76%  of
he organisms  were  susceptible  (range  0—93.8%)
r
f
p
h
n
t
u
a
p
w
t
t
i
i
H
s
p
i
c
t
n
i
t
c
T
t
r
l
r
p
i
t
m
t
A
T
m
a
R462  
to  any  antituberculor  drugs  and  that  13%  were
MDR-TB (range  0—54.4%),  while  the  corresponding
values for  the  second  surveillance  were  77%  (range
6—100%)  and  9.3%  (0—48.23%),  respectively.  The
third surveillance  reported  values  of  82%  and  7%
(0—58.3%),  respectively.  In  the  fourth  surveillance
report, resistance  to  at  least  one  anti-tuberculosis
drug (any  resistance)  ranged  from  0%  in  three  Euro-
pean countries  to  85.9%  in  Tashkent,  Uzbekistan.
The highest  proportions  of  MDR  were  reported  in
Tashkent,  Uzbekistan  (60.0%),  and  Baku,  Azerbai-
jan (55.8%).  New  data  on  previously  treated  cases
from Gujarat  State,  India,  indicated  that  17.2%  of
the isolates  were  MDR-TB  [21].
In the  present  study,  the  INH  resistance  in  previ-
ously  treated  cases  was  found  to  be  49.7,  66.6,  and
43.8% in  isolates  from  SA-1,  SA-2,  and  SA-3,  respec-
tively. In  isolates  from  SA-1  and  SA-3,  INH  resistance
was similar  but  lower  than  that  of  isolates  from  SA-
2. This  result  may  be  because  only  six  isolates  were
studied in  SA-2.  In  the  Thiruvallur  district,  an  INH
resistance  of  37%  has  been  reported  [13]. A  higher
INH resistance  has  also  been  reported  in  Ahmed-
abad, Gujarat  (57.18%),  and  the  North  Arcot  district
(67%) [33,41].
Rifampicin  resistance  in  SA-1,  SA-2,  and  SA-3
was found  in  39.5,  66.6,  and  43.8%  of  the  isolates,
respectively.  Our  ﬁndings  showed  higher  resis-
tance to  rifampicin  compared  with  the  results  from
Ahmedabad,  Gujarat  (37.47%);  New  Delhi  (26.73%);
and the  North  Arcot  district  (12%)  [33,35,41].
Acquired MDR-TB  was  present  in  35.7,  66.6,  and
43.8% of  all  previously  treated  cases  from  SA-1,
SA-2, and  SA-3,  respectively.  Our  ﬁndings  were  com-
parable to  those  of  other  Indian  studies.  Our  study
showed  a  slightly  higher  number  of  MDR  cases  com-
pared  with  the  results  from  Gujarat  (33.8%),  New
Delhi (33.7%),  Jaipur  (23.4%),  Thiruvallur  (11.7%),
and the  North  Arcot  district  (11%)  [13,24,41]  and  a
lower number  of  MDR  cases  that  those  reported  in
North Arcot  (69%)  and  the  Raichur  district  (100%)
[21].  Shah  et  al.  (2002)  reported  similar  results
(32.97%) in  a  study  on  Ahmedabad  [33].  The  global
median  prevalence  of  acquired  MDR-TB  is  13%.
Additionally, no  acquired  resistance  was  found  in
Kenya [42].  Our  study  showed  35.0,  66.6,  and  50.0%
ethambutol  resistance  in  isolates  from  SA-1,  SA-2,
and SA-3,  respectively.  Similarly,  a study  in  Gujarat
reported  ethambutol  resistance  in  35.45%  of  iso-
lates [33].
In previously  treated  patients,  streptomycin
resistance  was  found  in  41.8,  50.0,  and  37.5%  of
the isolates  from  SA-1,  SA-2,  and  SA-3,  respec-
tively. In  the  North  Arcot  district,  the  TRC  observed
that 26%  of  patients  were  resistant  to  streptomycin
[41].  A  study  in  Ahmedabad,  Gujarat,  revealedJ.P.  Mathuria  et  al.
esistance  to  streptomycin  in  35.58%  of  isolates
rom previously  treated  cases  [33], which  is  com-
arable to  our  results.  The  likely  reason  for  this
igh level  of  resistance  could  be  the  indiscrimi-
ate use  of  streptomycin-containing  regimens  for
he treatment  of  tuberculosis  in  earlier  programs
nder non-DOT  situations  in  both  the  government
nd private  sectors  [31].
In the  present  study,  we  found  that  many  of  the
atients with  resistance  to  isoniazid  and  rifampicin
ere also  resistant  to  other  drugs,  such  as  strep-
omycin and  ethambutol.  These  results  emphasize
he importance  of  using  at  least  four  drugs  in  the
nitial phase  of  pulmonary  tuberculosis  treatment
n areas  with  a high  prevalence  of  drug  resistance.
The DOTS  strategy  is the  basis  of  good  TB  control.
owever, the  strategy  should  be  modiﬁed  in  some
ettings  to  identify  drug-resistant  cases  in  the  initial
hase of  therapy.  Second-line  drugs  should  be  used
n appropriate  treatment  regimens  to  treat  these
ases [22].
Access  to  diagnosis  and  managed  care  of  TB
hrough the  participation  of  private  providers  is  a
ew paradigm  in  health  care  that  ensures  DOTS
mplementation.  This  paradigm  results  in  high
reatment  success  rates  and  lower  drug  resistance.
In the  present  study,  we  found  a higher  per-
entage of  MDR  cases  in  previously  treated  cases.
his result  could  be  because  our  hospital  is  a  ter-
iary care  center  and  the  majority  of  cases  are
eferred patients.  Furthermore,  the  higher  preva-
ence of  MDR-TB  in  this  group  may  indicate  more
ecent transmission  of  drug-resistant  strains  com-
ared with  the  reactivation  of  an  infection  acquired
n the  past.  Careful  attention  needs  to  be  paid  to
he more  efﬁcient  use  of  existing  treatment  regi-
ens according  to  established  guidelines  to  reduce
he burden  of  drug  resistance  in  the  community.
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